307 related articles for article (PubMed ID: 11531260)
21. Biochemical genetic analysis of indanocine resistance in human leukemia.
Hua XH; Genini D; Gussio R; Tawatao R; Shih H; Kipps TJ; Carson DA; Leoni LM
Cancer Res; 2001 Oct; 61(19):7248-54. PubMed ID: 11585762
[TBL] [Abstract][Full Text] [Related]
22. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI
Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766
[TBL] [Abstract][Full Text] [Related]
23. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
Speicher LA; Barone L; Tew KD
Cancer Res; 1992 Aug; 52(16):4433-40. PubMed ID: 1353706
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
25. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells.
Gökmen-Polar Y; Escuin D; Walls CD; Soule SE; Wang Y; Sanders KL; Lavallee TM; Wang M; Guenther BD; Giannakakou P; Sledge GW
Cancer Res; 2005 Oct; 65(20):9406-14. PubMed ID: 16230404
[TBL] [Abstract][Full Text] [Related]
26. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of tubulin isotypes during the cell cycle.
Dumontet C; Durán GE; Steger KA; Murphy GL; Sussman HH; Sikic BI
Cell Motil Cytoskeleton; 1996; 35(1):49-58. PubMed ID: 8874965
[TBL] [Abstract][Full Text] [Related]
28. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes.
Derry WB; Wilson L; Khan IA; Luduena RF; Jordan MA
Biochemistry; 1997 Mar; 36(12):3554-62. PubMed ID: 9132006
[TBL] [Abstract][Full Text] [Related]
29. Over-expression of betaI tubulin in MDCK cells and incorporation of exogenous betaI tubulin into microtubules interferes with adhesion and spreading.
Lezama R; Castillo A; Ludueña RF; Meza I
Cell Motil Cytoskeleton; 2001 Nov; 50(3):147-60. PubMed ID: 11807936
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs.
Carles G; Braguer D; Dumontet C; Bourgarel V; Gonçalves A; Sarrazin M; Rognoni JB; Briand C
Br J Cancer; 1999 Jun; 80(8):1162-8. PubMed ID: 10376967
[TBL] [Abstract][Full Text] [Related]
31. Estramustine depolymerizes microtubules by binding to tubulin.
Dahllöf B; Billström A; Cabral F; Hartley-Asp B
Cancer Res; 1993 Oct; 53(19):4573-81. PubMed ID: 8402630
[TBL] [Abstract][Full Text] [Related]
32. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
33. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.
Ranganathan S; Benetatos CA; Colarusso PJ; Dexter DW; Hudes GR
Br J Cancer; 1998 Feb; 77(4):562-6. PubMed ID: 9484812
[TBL] [Abstract][Full Text] [Related]
34. Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells.
Yang CC; Hsu CP; Yang SD
Clin Cancer Res; 2000 Mar; 6(3):1024-30. PubMed ID: 10741730
[TBL] [Abstract][Full Text] [Related]
35. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
[TBL] [Abstract][Full Text] [Related]
36. Modulation of paclitaxel resistance by annexin IV in human cancer cell lines.
Han EK; Tahir SK; Cherian SP; Collins N; Ng SC
Br J Cancer; 2000 Jul; 83(1):83-8. PubMed ID: 10883672
[TBL] [Abstract][Full Text] [Related]
37. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry.
Verdier-Pinard P; Wang F; Burd B; Angeletti RH; Horwitz SB; Orr GA
Biochemistry; 2003 Oct; 42(41):12019-27. PubMed ID: 14556633
[TBL] [Abstract][Full Text] [Related]
38. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid.
Wang Y; Veeraraghavan S; Cabral F
Biochemistry; 2004 Jul; 43(28):8965-73. PubMed ID: 15248754
[TBL] [Abstract][Full Text] [Related]
39. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
[TBL] [Abstract][Full Text] [Related]
40. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
